Johnson & Johnson’s CEO laid down a big bet: cancer can be beaten or tamed in the years ahead. This piece tracks that claim, the real-world gains already visible in certain blood cancers, the role of immune-based therapies and AI, and how corporate moves like the Firefly Bio buy hint at a strategy focused on hard-to-treat mutations and longer, healthier lives.
Speaking at the WSJ Leadership Institute CEO Summit in London, Joaquin Duato put a clear timeline on the company’s ambition and did not hedge. He said the aim in the next decade is to “try to eliminate cancer,” a short, fierce mission statement that pushes the industry to stop treating incurability as inevitable. The room took it as more than rhetoric because J&J is pairing drug science with systems-level investments.
Duato pointed to areas where progress is already obvious, using multiple myeloma as a concrete example of rapid change. Once measured in single years of life expectancy, many patients are now living a decade or longer thanks to new classes of therapy and smarter combinations. “We have treatments now that utilize your own immune system to attack the cancer,” he said at the summit, and those therapies are rewriting outcomes for people who previously had no options.
The real-world anecdotes are hard to ignore and they arrive with stark numbers attached. “For patients who were already going into hospice, so they didn’t have any other alternative, they are [at] more than five years, with a single administration, in remission. That [is] spectacular.” Stories like that shift the conversation from incremental improvement to genuine possibility and make the hunt for scalable cures a clear business and moral priority.
Duato highlighted how patients react when treatments actually change trajectories. “When patients see that, they cannot believe that because they have been coming to the hospital every week [for] a decade, having multiple therapies.” That disbelief is a signal—science is starting to give back long stretches of normal life, and companies are racing to turn those wins into broader, repeatable strategies. “It’s realistic to believe that we are going to cure certain cancers, and some others we’re going to turn into chronic diseases,” he predicted, framing the future as a mix of eradication and durable management.
The conversation didn’t stop at oncology; Duato also called out dementia as another major target for future innovation and argued that rising life expectancy will make longevity technologies a central focus. J&J is betting on data, biology, and digital tools to raise both lifespan and healthspan. He singled out artificial intelligence as a potential “force multiplier” that can accelerate discovery, diagnostics, and individualized care.
On that point, Fox News senior medical analyst Dr. Marc Siegel echoed the direction and added clinical texture to the corporate view. “Advances [will be] based on the use of AI to help guide targeted treatments with expanding knowledge of cancer mutations and how to target them,” he predicted, speaking to Fox News Digital. He also noted that biomarkers and AI-guided decision-making could catch cancers earlier and make surgery and other interventions far more precise and personalized.
The strategy is visible on the balance sheet too: J&J recently acquired Firefly Bio, a company focused on payloads that enter cancer cells and “target certain proteins that contain difficult to treat gene mutations.” That move signals a two-front approach—develop the deep biology to hit stubborn mutations while building platform tools, like AI and biomarkers, to find and treat patients sooner. Combined, those priorities paint a picture of an industry shifting from managing decline to engineering long-term remission and, for some cancers, outright cures.
